These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 30846557

  • 1. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
    Block GA, Rosenbaum DP, Yan A, Chertow GM.
    J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
    [Abstract] [Full Text] [Related]

  • 2. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE, Rosenbaum DP, Yang Y, Chertow GM.
    J Am Soc Nephrol; 2021 Jun 01; 32(6):1465-1473. PubMed ID: 33766811
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
    Block GA, Rosenbaum DP, Yan A, Greasley PJ, Chertow GM, Wolf M.
    Nephrol Dial Transplant; 2019 Feb 01; 34(2):339-346. PubMed ID: 29617976
    [Abstract] [Full Text] [Related]

  • 6. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
    Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Stefansson BV, Rydén-Bergsten T, Greasley PJ, Johansson SA, Knutsson M, Carlsson BC.
    Clin J Am Soc Nephrol; 2016 Sep 07; 11(9):1597-1605. PubMed ID: 27340281
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.
    Nakayama M, Kobayashi S, Kusakabe M, Ohara M, Nakanishi K, Akizawa T, Fukagawa M.
    Clin Exp Nephrol; 2024 Feb 07; 28(2):153-164. PubMed ID: 37910313
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. An update on tenapanor to treat hyperphosphatemia.
    Cianciolo G, Barbuto S, Iacovella F, La Manna G, Galassi A, Ciceri P, Cozzolino M.
    Drugs Today (Barc); 2022 Jan 07; 58(1):33-53. PubMed ID: 35107092
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tenapanor: First Approval.
    Markham A.
    Drugs; 2019 Nov 07; 79(17):1897-1903. PubMed ID: 31677150
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.